ArticleBMC cancer2025
Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
backgroundAdjuvant therapies are now considered standard care for high-risk melanoma patients. It is urgent to identify reliable biomarkers to select patients at high risk of relapse, who will derive more benefit from adjuvant therapy.
methodsTargeted next-generation sequencing using a 437 cancer-related gene panel was performed on primary tumor samples from 55 patients in stage I-III melanoma and postsurgical plasma samples from 46 patients. Association analysis of clinico-genomic characteristics with disease-free survival was conducted.
resultsThe median DFS was 39.2 months (rangement: 1.4-49.7 months). Patients receiving anti-PD-1 adjuvant therapy had a longer DFS than those receiving adjuvant interferon therapy (mDFS, NA vs. 21.3 months, HR 0.36 [95% CI: 0.13-1.03], P = 0.047). No significant correlation of DFS with driver mutations in BRAF, NRAS and KIT was observed. Chromosomal instability score (CIS) was identified as an independent predictive factor of DFS following adjustment for clinical and genetic factors (HR 4.06 [95% CI: 1.28-12.89], P = 0.017), with an inferior DFS observed in patients with high CIS compared with the CIS-low patients (mDFS, 14.3 vs. 49.7 months, HR 3.90 [95%CI: 1.40-11.00], P = 0.005). In addition, patients with a maxVAF > 1% in the postsurgical ctDNA had a worse DFS compared with those with a maxVAF ≤1% (mDFS, 11.0 vs. 49.7 months, HR 3.70 [95% CI: 1.20-11.00], P = 0.012). Finally, CIS and postsurgical ctDNA status were considered as independent factors for recurrence risk in stage I-III melanoma.
conclusionIdentification of clinical and genetic biomarkers for recurrence risk prediction in resected melanoma may aid in clinical decision-making for early disease monitoring and optimal design of therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.